Endo Pharmaceuticals appoints former Pfizer, Moksha8 exec to EVP, CFO
CHADDS FORD, Pa. Endo Pharmaceuticals has appointed an executive from Pfizer and Moksha8 Pharmaceuticals to two executive positions, the company announced Thursday.
The company appointed Alan Levin as EVP and CFO. Levin was previously SVP and CFO of Pfizer, where he worked for 20 years in various executive positions. He was also EVP and CFO of Moksha8, a privately held company focused on Latin America and other emerging markets.
“I am very excited to be joining Endo Pharmaceuticals,” Levin stated. “The company has tremendous potential and is uniquely positioned to take advantage of the many opportunities for growth, diversification and value creation that we see in the marketplace.”
OSI Pharmaceuticals EVP to present portfolio at diabetes and obesity conference
MELVILLE, N.Y. OSI Pharmaceuticals, Inc. announced Thursday that Anker Lundemose, M.D., EVP of OSI Pharmaceuticals will present at the Canaccord Adams Conference in New York, N.Y. on Tuesday, May 12, 2009 at 8:40 a.m. (Eastern Time).
Lundemose will provide an overview on the company’s diabetes/obesity product portfolio and business developments.
OSI Pharmaceuticals discover, develop and commercialize high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
FDA grants priority review to Prevnar 13
COLLEGEVILLE, Pa. The Food and Drug Administration has granted priority review to Wyeth Pharmaceuticals’ application for the pneumococcal vaccine Prevnar 13 (diphtheria CRM protein).
The company submitted the application for the vaccine, a 13-valent conjugate vaccine, on March 31.
Wyeth said it is seeking approval for Prevnar 13 for the prevention of invasive pneumococcal disease and otitis media caused by the 13 serotypes in the vaccine in children ages 2 months to 5 years. Prevnar 13 includes six serotypes in addition to the seven in the earlier version of Prevnar.
“Since its launch in 2000, our seven-valent pneumococcal vaccine, Prevnar, has significantly reduced the incidence of pneumococcal disease among infants and young children in the United States,” Wyeth Pharmaceuticals EVP vaccine research and development Emilio Emini said. “Recently, however, disease due to pneumococcal serotypes not found in Prevnar, particularly serotype 19A, have increased in prevalence in many regions of the world and are a significant public health concern.”